PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.10%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-6.32%
Negative gross profit growth while MRVL is at 2.26%. Joel Greenblatt would examine cost competitiveness or demand decline.
-22.67%
Negative EBIT growth while MRVL is at 494.07%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-22.67%
Negative operating income growth while MRVL is at 494.07%. Joel Greenblatt would press for urgent turnaround measures.
-31.20%
Negative net income growth while MRVL stands at 5309.05%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-33.33%
Negative EPS growth while MRVL is at 5354.55%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-37.50%
Negative diluted EPS growth while MRVL is at 4900.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.13%
Share reduction more than 1.5x MRVL's 1.85%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
6.67%
Diluted share count expanding well above MRVL's 5.77%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-42.47%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-131.26%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
926.57%
10Y revenue/share CAGR 1.25-1.5x MRVL's 738.45%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
143.90%
5Y revenue/share CAGR at 50-75% of MRVL's 285.72%. Martin Whitman would worry about a lagging mid-term growth trajectory.
79.87%
3Y revenue/share CAGR at 75-90% of MRVL's 104.43%. Bill Ackman would expect new product strategies to close the gap.
2599.56%
10Y OCF/share CAGR above 1.5x MRVL's 1062.91%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
207.67%
5Y OCF/share CAGR 1.25-1.5x MRVL's 167.81%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
47.63%
3Y OCF/share CAGR at 50-75% of MRVL's 75.23%. Martin Whitman would suspect weaker recent execution or product competitiveness.
1673.48%
Net income/share CAGR above 1.5x MRVL's 946.12% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
666.76%
5Y net income/share CAGR at 50-75% of MRVL's 1195.83%. Martin Whitman might see a shortfall in operational efficiency or brand power.
149.80%
3Y net income/share CAGR above 1.5x MRVL's 2.09%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
2155.17%
Below 50% of MRVL's 7959.39%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
143.96%
5Y equity/share CAGR above 1.5x MRVL's 45.85%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
102.52%
3Y equity/share CAGR above 1.5x MRVL's 27.11%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.20%
Firm’s AR is declining while MRVL shows 8.16%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
17.18%
We show growth while MRVL is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
1.60%
Asset growth 1.25-1.5x MRVL's 1.30%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
4.42%
BV/share growth above 1.5x MRVL's 1.82%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
11.74%
We increase R&D while MRVL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
1.94%
We expand SG&A while MRVL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.